Objective. D prostanoid receptor 1 (DP1), a receptor for prostaglandin D 2 , plays important roles in inflammation and cartilage metabolism. However, its role in the pathogenesis of osteoarthritis (OA) remains unknown. This study was undertaken to explore the roles of DP1 in the development of OA in murine models and to evaluate the efficacy of a DP1 selective agonist in the treatment of OA.
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Objective. D prostanoid receptor 1 (DP1), a receptor for prostaglandin D 2 , plays important roles in inflammation and cartilage metabolism. However, its role in the pathogenesis of osteoarthritis (OA) remains unknown. This study was undertaken to explore the roles of DP1 in the development of OA in murine models and to evaluate the efficacy of a DP1 selective agonist in the treatment of OA.
Methods. The development of aging-associated OA and destabilization of the medial meniscus (DMM)-induced OA was compared between DP1-deficient (DP1
2/2
) and wild-type (WT) mice. The progression of OA was assessed by histology, immunohistochemistry, and micro-computed tomography. Cartilage explants from DP1
2/2 and WT mice were treated with interleukin-1a (IL-1a) ex vivo, to evaluate proteoglycan degradation. The effect of intraperitoneal administration of the DP1 selective agonist BW245C on OA progression was evaluated in WT mice.
Results. Compared to WT mice, DP1
2/2 mice had exacerbated cartilage degradation in both models of OA, and this was associated with increased expression of matrix metalloproteinase 13 and ADAMTS-5. In addition, DP1
2/2 mice demonstrated enhanced subchondral bone changes. Cartilage explants from DP1 2/2 mice showed enhanced proteoglycan degradation following treatment with IL-1a. Intraperitoneal injection of BW245C attenuated the severity of DMM-induced cartilage degradation and bony changes in WT mice.
Conclusion. These findings indicate a critical role for DP1 signaling in OA pathogenesis. Modulation of the functions of DP1 may constitute a potential therapeutic target for the development of novel OA treatments.
Osteoarthritis (OA) is the most common degenerative disorder and a leading cause of physical disability (1) , with a large socioeconomic cost (2) . Clinical manifestations of OA may include pain, stiffness, and reduced joint motion. Pathologically, OA is characterized by progressive degeneration of the articular cartilage, increased expression of inflammatory and catabolic mediators, and subchondral bone remodeling (3) . At present, there is no curative therapy available for OA and current treatment remains limited to symptomatic relief. A variety of risk factors, including joint injury, obesity, aging, and genetics, have been associated with OA (1); however, the pathophysiologic processes that contribute to the progressive nature of the disease remain elusive. A deeper understanding of the mechanisms underlying OA development will be instrumental in developing novel drugs for the prevention and treatment of OA.
Degradation of the cartilage extracellular matrix is a central feature of OA and is considered to be mediated by proteinases that degrade major structural components of the matrix, primarily type II collagen and aggrecan. Matrix metalloproteinase 13 (MMP-13) is the principal protease responsible for type II collagen degradation, and MMP-13-deficient mice are protected against OA cartilage damage (4), whereas MMP-13-transgenic mice develop spontaneous OA-like cartilage damage (5) . ADAMTS-5 is the main aggrecan-degrading proteinase in murine cartilage, and ADAMTS-5-deficient mice are protected from surgically induced OA (6) and from inflammatory arthritis (7) .
Prostaglandin D 2 (PGD 2 ) is a potent lipid mediator derived from arachidonic acid via cyclooxygenases and PGD 2 synthases. PGD 2 elicits its downstream effects by activating 2 plasma membrane receptors, D prostanoid receptor 1 (DP1) (8) and chemoattractant receptorlike molecule expressed on Th2 cells (CRTH2), also known as DP2 (9) . PGD 2 contributes to multiple physiologic and pathologic processes, including vasodilation (10), platelet aggregation (11), smooth muscle relaxation and contraction (12) , sleep/wake regulation (13), mediation of allergic reactions (14) , chemotaxis (9) , and cell trafficking (15) . PGD 2 has also been shown to modulate inflammation, acting as either a proinflammatory or antiinflammatory mediator, depending on the pathologic condition and the affected tissue. Activation of DP1 receptors is primarily associated with antiinflammatory effects (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) . In contrast, activation of DP2 is generally associated with proinflammatory effects (9, (25) (26) (27) (28) (29) (30) (31) (32) (33) .
We have previously shown that DP1 is expressed in human cartilage and that the selective DP1 agonist BW245C inhibits interleukin-1 (IL-1)-induced expression of MMP-1 and MMP-13 in cultured chondrocytes (34) , suggesting that DP1 may play a protective role in OA pathogenesis. To test this hypothesis, we investigated the effect of DP1 deletion on the course of agingassociated spontaneous OA and instability-induced OA in 2 murine models. We also examined the effect of the DP1 selective agonist BW245C on the progression of instability-induced OA in wild-type (WT) mice. The results of this study demonstrate that DP1 deletion exacerbated cartilage degradation in both the agingassociated and instability-induced OA models. The effect of DP1 deficiency was associated with increased expression of MMP-13 and ADAMTS-5. We also showed that OA-like bony changes were more pronounced in DP1 2/2 mice compared to WT mice. Furthermore, we demonstrated that administration of a DP1 agonist attenuated the severity of OA-like features. Taken together, these findings suggest that targeting DP1 could represent a promising new avenue in the development of novel therapies for OA.
MATERIALS AND METHODS
Mice. All animal experiments were approved by the Institutional Animal Protection Committee of the University of Montreal Hospital Research Centre. DP1 2/2 mice were generated as described previously (14) . In those mice, the DP1 gene was disrupted by insertion of a neomycin resistance gene into the first coding exon (exon 2) between the Nhe I and Xba I restriction sites. This modification leads to complete loss of functional DP1 protein in homozygous animals. DP1 2/2 mice were backcrossed onto the C57BL/6 background for more than 10 generations. Heterozygous mice were intercrossed to obtain the DP1 2/2 mice and WT littermates used in the experiments. Genotypes were identified by polymerase chain reaction (PCR) analyses of tail biopsy DNA extract.
Mice were maintained under standard pathogen-free conditions at a constant temperature of 218C (618C) and a 12-hour light/dark cycle, with water and a pelleted standard normal diet (catalog no. 2918; Teklad Global, Harlan Laboratories) made available ad libitum. Mice were housed 2-5 per cage in filter-top cages (;38 3 20 3 15 cm in dimension) containing hardwood chip (Beta Chip; Northeastern Products) or Teklad 7089 diamond soft cellulose bedding (Harlan Laboratories) for the studies of aging-associated OA and destabilization of the medial meniscus (DMM)-induced OA, respectively. Cotton nestlets and hard plastic tubes were placed in each cage for environmental enrichment.
Aging-associated and instability-induced OA models. In the aging-associated model of OA, groups of WT and DP1 2/2 mice were killed at ages 3, 9, and 15 months. Knees were harvested and subjected to histologic, immunohistochemical, and micro-computed tomography (micro-CT) analyses.
For the DMM model of OA, arthritis was induced in the right knee joints of 10-week-old male WT and DP1 2/2 mice, as described previously (35) . Briefly, animals were anesthetized and the right knee joint was destabilized by transection of the anterior attachment of the medial meniscotibial ligament (MMTL). The sham operation involved the same surgery, except that the MMTL was visualized but not transected. Buprenorphine was provided perioperatively at 0.09 mg/kg every 10-12 hours for 72 hours. Groups of mice were killed at 2, 4, and 8 weeks post-DMM surgery, and the joints were evaluated for the development of OA. Only male mice were used in vivo in this study, because male mice develop more prominent features of the disease (36) . Nine mice were excluded from this study due to spontaneous death (n 5 3), anesthesia-associated death (n 5 2), postoperative complications (n 5 2), or incomplete decalcification (n 5 2).
Histologic analysis of cartilage. The harvested knee joints were fixed in TissuFix (Chaptec), decalcified in RDO Rapid Decalcifier (Apex Engineering), and embedded in paraffin. Coronal sections (5 mm) were obtained through the entire joint at 80-mm intervals and stained with Safranin O-fast green (Sigma-Aldrich). Eight sections of joint tissue from each mouse were graded by 2 scorers (YO and HF) who were blinded with regard to the origin of the specimens, in accordance with the recommendations of the Osteoarthritis Research Society International (OARSI) guidelines (37 Isolation of primary chondrocytes and measurement of cAMP levels. Primary epiphyseal chondrocytes were isolated from 5-6-day-old mice, as previously reported (40) . A detailed description of the isolation of the primary chondrocytes can be found in the Supplementary Methods (http:// onlinelibrary.wiley.com/doi/10.1002/art.40160/abstract).
RNA extraction and real-time reverse transcription-PCR (RT-PCR). Articular cartilage was dissected from the surfaces of the tibial plateaus and femoral condyles using a scalpel blade under a dissecting microscope. Cartilage pieces from 5 separate mouse joints (for the aging studies) or 8 separate mouse joints (for the DMM studies) were pooled for each sample of RNA, and 3 samples were used per experimental group. Total RNA was isolated using TRIzol reagent (Invitrogen), according to the manufacturer's instructions. RNA was reverse transcribed and amplified using a QuantiTect RT-PCR kit (Qiagen) on a Rotor Gene 3000 real-time PCR system (Corbett Research), according to the manufacturer's protocol. Relative messenger RNA (mRNA) expression was determined using the DDC t method, and GAPDH was used as the housekeeping gene. The primer efficiencies were similar for the target and GAPDH genes (a list of all primer sequences is available from the corresponding author upon request).
Culture of cartilage explants. Femoral heads from 3-4-week-old WT and DP1 2/2 mice were cultured as explants (4 femoral heads per well) in 48-well plates at 378C in 400 ml of Dulbecco's modified Eagle's medium (DMEM) containing antibiotics and 10% fetal calf serum for 48 hours. The explants were then washed in serum-free DMEM and cultured for an additional 72 hours in serum-free DMEM, with or without 10 ng/ml mouse IL-1a. Conditioned medium was collected at the end of the culture period, and proteoglycan degradation was assessed by measuring the levels of sulfated glycosaminoglycan (GAG) released into the culture medium, using dimethylmethylene blue with chondroitin sulfate as a standard (41) . Results are expressed as mg of GAG released/mg cartilage.
Micro-CT analysis of bone. The knee joints were scanned using a Skyscan 1176 micro-CT scanner at 50 KV and 149 mA, with a pixel size of 9 mm and a 0.5-mm aluminum filter. Data were recorded at every 3-degree rotation step through 180 degrees. Image slices were reconstructed using NRecon software (version 1.6.3.2; SkyScan). The region of interest included the area between the epiphyseal growth plate and the articular cartilage. Using SkyScan CT Analyzer software, the following bone morphometric parameters were assessed: trabecular bone volume fraction (bone volume/total volume [BV/TV]), trabecular thickness (TbTh), trabecular separation (TbSp), and trabecular number (TbN). CTVox software (SkyScan) was used to create 3-dimensional (3-D) images.
Statistical analysis. Statistical analysis was performed using GraphPad Prism software, version 6.0. Comparison between groups was performed using the Mann-Whitney U test or Student's t-test. P values less than 0.05 were considered significant.
RESULTS
Acceleration of cartilage degeneration in DP1-deficient mice in the aging-associated and DMMinduced OA models. We first examined the expression of DP1 and CRTH2 mRNA in articular cartilage of WT mice at 8 weeks post-DMM surgery (n 5 3 replicate experiments, with 8 joints pooled per replicate) and at 9 months of age (n 5 3 replicate experiments, with 5 joints pooled per replicate). Expression of mRNA was evaluated as a percentage relative to the values in control animals (sham-operated or 3-month-old mice) after normalization to the values for the GAPDH internal control gene. We found that the level of DP1 mRNA was significantly lower in mice at 8 weeks post-DMM and mice at age 9 months (see results in Supplementary Figures 1A and B , available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10. 1002/art.40160/abstract). In contrast, the expression level of CRTH2 mRNA remained unchanged. These data suggest that decreased expression of DP1 in OA chondrocytes might be involved in the pathophysiology of OA.
The findings prompted us to analyze the effect of functional DP1 deletion on the development of OA-like changes in mice. In these studies, the effective deletion of the functional DP1 receptor was validated by assessing its ability to mediate cAMP production, a functional readout for DP1 activation. The results revealed that treatment with either PGD 2 or BW245C enhanced the levels of cAMP in cultured chondrocytes from WT mice, whereas in DP1 2/2 mice, the levels of cAMP remained unchanged following treatment with these 2 agonists. Treatment with other agonists that induce cAMP production, such as PGE 2 , increased the cAMP levels in both WT and DP1 2/2 mouse chondrocytes (see Supplementary Figure 1C , http:// onlinelibrary.wiley.com/doi/10.1002/art.40160/abstract). Thus, the results confirmed the loss of functional DP1 activity in chondrocytes from DP1 2/2 mice. To investigate whether DP1 deficiency affects the expression of the genes for types I and II collagen and aggrecan, we analyzed their mRNA levels in primary chondrocytes isolated from DP1 2/2 and WT mice. Real-time RT-PCR analysis showed no significant differences in the mRNA expression levels for any of these genes between DP1
2/2 and WT mouse chondrocytes (see Supplementary Figure 1D , http://onlinelibrary. wiley.com/doi/10.1002/art.40160/abstract), indicating that the deletion of DP1 does not alter the expression of the key components of cartilage matrix in cultured chondrocytes.
To define the role of DP1 in the development of OA, we next compared histologic features in the knee joints of WT and DP1 2/2 mice at ages 3, 9, and 15 months (n 5 6 mice per genotype at each time point). Knee joints from WT mice showed no anomalies in the cartilage until age 15 months, when only a mild decrease in Safranin O staining and small fibrillations were seen. In contrast, DP1
2/2 mouse joints showed a decrease in Safranin O staining accompanied by mild fibrillations as early as age 9 months, and almost complete loss of the articular cartilage at age 15 months ( Figures 1A and B) .
We also evaluated the condition of the articular cartilage of WT and DP1 2/2 mice using the OARSI histologic scoring system (37) . At age 3 months, there was no difference in the summed histologic score for OA severity between DP1 2/2 mice and their WT littermates. At ages 9 months and 15 months, the summed score for the articular cartilage of DP1 2/2 mice was significantly higher than that for the articular cartilage of WT littermates at the same age ( Figure 1C ). These data suggest that DP1 deficiency accelerates the progression of spontaneous aging-related cartilage degeneration.
We next examined the susceptibility of 10-weekold DP1 2/2 mice and their WT littermates to DMMinduced OA. DMM surgery was performed and the knee joints were harvested at 2 weeks (n 5 8 WT mice and 8 DP1 2/2 mice), 4 weeks (n 5 7 WT mice and 6 DP1 2/2 mice), and 8 weeks (n 5 8 WT mice and 8 DP1 2/2 mice) postsurgery. Histologic analysis of the knee joints showed that features of cartilage degeneration appeared at 2 weeks after DMM surgery and worsened at 4 and 8 weeks (Figures 2A and B) . The changes were, however, significantly more severe in DP1 2/2 mice. Quantification by the OARSI scoring system (37) confirmed the severity of cartilage lesions observed in DP1 2/2 mice at all postsurgery time points analyzed ( Figure 2C ). Taken together, these data indicate that DP1 deletion also accelerates cartilage destruction in the DMM model.
As shown in Figures 2A and B, osteophytes were detected at the medial edge of the joints of both WT and DP1
2/2 mice. The time course of osteophyte formation and the size of the osteophytes in DP1 2/2 mice were virtually similar to those in WT mice.
Up-regulated expression of cartilage degradation enzymes in the presence of DP1 deletion. To explore the mechanisms underlying the exacerbation of cartilage damage in DP1
2/2 mice, we analyzed the expression of key mediators of cartilage degradation, i.e., expression of ADAMTS-5 and MMP-13 (5-7), in DP1 2/2 mice and their WT littermates at ages 3 months and 9 months (n 5 5 mice per genotype per time point). At age 3 months, there was little or no expression of MMP-13 or ADAMTS-5 in the knee joints of either WT 2/2 mice ( Figures 3A and B) . At age 9 months, the expression levels of both enzymes remained barely detectable in the knee joints of WT mice, but the levels of both enzymes were dramatically elevated in the knee joints of DP1 2/2 mice ( Figures 3A and B) .
We also analyzed the expression of MMP-13 and ADAMTS-5 in the knee joints of sham-operated WT and DP1
2/2 mice (n 5 5 mice per genotype) and DMMoperated WT and DP1 2/2 mice (n 5 5 mice per genotype) at 2 weeks postsurgery. Results showed that the expression levels of these proteins were elevated in the knee joints of both DP1 2/2 and WT mice (see Supplementary Figures 2A-C , available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/ doi/10.1002/art.40160/abstract). Interestingly, the number of cells staining for MMP-13 and ADAMTS-5 was higher in DP1 2/2 mouse cartilage relative to WT mouse cartilage. The expression of these proteins was barely detectable in sham-operated knees.
To determine whether the observed immunohistochemical changes in protein expression were paralleled by changes at the mRNA level, we performed real-time PCR analyses. Consistent with the changes at the protein level, we found that the levels of MMP-13 and ADAMTS-5 mRNA were more elevated in DP1 2/2 mice compared to their WT littermates at age 9 months (n 5 3 replicate experiments, 5 joints per replicate) (Figure 3C) . The levels of MMP-13 and ADAMTS-5 mRNA were also more elevated in DP1 2/2 mice compared to their WT littermates at 2 weeks post-DMM surgery (n 5 3 replicate experiments, 8 joints per replicate) (see Supplementary Figure 2C , http://onlinelibrary. wiley.com/doi/10.1002/art.40160/abstract). Hence, deletion of the DP1 gene may exacerbate cartilage degradation by enhancing the expression of MMP-13 and ADAMTS-5.
Enhanced OA-like bony changes in DP1-deficient mice with spontaneous aging-associated OA. Micro-CT analyses were performed to evaluate the microarchitectural changes that occurred in the subchondral bone of WT and DP1 2/2 mice at ages 3 months and 15 months (n 5 6 mice per genotype per time point). Axial micro-CT scans of the medial tibiae of mice at age 3 months revealed no difference in the severity of subchondral bone sclerosis between WT and DP1 2/2 mouse joints. In contrast, scans of the medial tibiae of DP1 2/2 mice at age 15 months demonstrated dramatically more severe subchondral bone sclerosis as compared to that of age-matched WT mice ( Figure 4A ).
Morphometric parameters of the subchondral bone (i.e., the BV/TV, TbTh, and TbSp) in the central weight-bearing region of the medial plateau were also assessed. At age 3 months, there was no significant difference in any of these variables (BV/TV, TbTh, or TbSp) between WT and DP1 2/2 mice ( Figure 4B ). At age 15 months, the BV/TV and TbTh of DP1 2/2 mice were each significantly higher than those of WT mice. In contrast, the TbSp in DP1 2/2 mouse joints at age 15 months tended to decrease, although the difference was not statistically significant compared to WT mouse joints.
Furthermore, 3-D renderings of the tibiae showed that the knee joints from 15-month-old WT mice were largely intact, with clear joint space and no heterotropic ossification. In contrast, DP1 2/2 mice of the same age showed joint space narrowing, increased mineralization of the meniscus, sesamoid bone enlargement, and ectopic bone formation ( Figure 4C ).
We also evaluated subchondral bone microarchitectural changes in sham-operated WT and DP1 2/2 mice (n 5 6 mice per genotype) and DMM-operated WT and DP1
2/2 mice (n 5 8 mice per genotype) at 8 weeks postsurgery. As expected, subchondral bone sclerosis was found in the medial tibia of both WT and DP1 
DP1 IN AGING-ASSOCIATED AND INSTABILITY-INDUCED OA
The BV/TV and TbTh of the subchondral bone of the medial tibial plateau of DMM-operated mouse knees were each significantly higher compared to those of sham-operated control mouse knees at 8 weeks postsurgery, both in WT mice and in DP1 2/2 mice, whereas the TbSp of the subchondral bone of DP1 2/2 mice was slightly lower, but not significantly different from, that of WT mice (see Supplementary Figure 3B , http://onlinelibrary.wiley.com/doi/10.1002/art.40160/ abstract). It is noteworthy that the magnitude of these changes was more pronounced in DP1 2/2 mice. The 3-D renderings of the tibiae of shamoperated and DMM-operated WT and DP1 2/2 mice showed meniscal calcification, sesamoid bone enlargement, and periarticular mineralization, which were more pronounced in DP1 2/2 mice (see Supplementary Figure 3C , http://onlinelibrary.wiley.com/doi/10.1002/ art.40160/abstract). The sham-operated control knees from both genotypes showed no changes in bone parameters or integrity.
Enhancement of IL-1a-induced proteoglycan degradation with DP1 deletion. To further understand the mechanisms of increased cartilage degradation in DP1 2/2 mice, we performed in vitro experiments using cartilage explants from WT and DP1 2/2 mice (n 5 3 replicate experiments, 2 mice per sample). The cartilage was left untreated or treated with IL-1a for 3 days, and proteoglycan degradation (i.e., the rate of GAG release) was determined. In the absence of any treatment, proteoglycan degradation in DP1 2/2 mouse cartilage was comparable to that in WT mouse cartilage ( Figure 5 ). In the presence of IL-1a, there was a marked increase in proteoglycan degradation in cartilage explants from both DP1 2/2 mice and WT mice compared to untreated controls. The rate of proteoglycan degradation was significantly higher in DP1 2/2 mouse explants ( Figure 5 ). These results further confirm that DP1 deletion enhances the release of catabolic enzymes and cartilage degradation.
Attenuation of DMM-induced OA using the DP1 agonist BW245C. We next examined the effect of BW245C, a selective agonist of DP1, on OA progression in WT mice subjected to sham surgery (n 5 7 mice per group) or DMM surgery (n 5 8 mice per group). Starting on 1 day postsurgery, mice were intraperitoneally injected daily with phosphate buffered saline (PBS) as a vehicle control or BW245C (0.5 mg/kg body weight per day; injection volume 0.2 ml) for 8 weeks. Treatment with BW245C, but not with the PBS vehicle control, decreased the severity of cartilage lesions ( Figures  6A and B) . Moreover, OARSI scoring consistently confirmed that the BW245C injection significantly suppressed the histologic severity of OA in DMM-operated mouse joints ( Figure 6B ).
In addition to its attenuating effects on articular cartilage destruction, intraperitoneal administration of BW245C reduced OA-related bony changes ( Figure  6C ). There were no structural changes in shamoperated knees treated with the PBS vehicle control or BW245C. These results indicate that intraperitoneal administration of BW245C exerts a protective effect against the pathogenesis of OA, including a reduction in the severity of articular cartilage destruction and subchondral bone changes.
DISCUSSION
In this study, we demonstrated that mice deficient in DP1 showed increased cartilage degradation with age or following DMM knee surgery. This effect of DP1 deletion was associated with enhanced expression of MMP-13 and ADAMTS-5 and with pronounced changes in the subchondral bone parameters. Moreover, we demonstrated that administration of a DP1 agonist exerted a protective effect against DMM-induced OA in WT mice.
Histologic examination revealed that cartilage structural damage was relatively more severe in DP1 2/2 mice compared to WT mice in both models of OA. To determine the mechanism underlying the effect of DP1 deficiency on cartilage degradation, we analyzed the levels of ADAMTS-5 and MMP-13, key proteases of cartilage extracellular matrix degradation (5-7). Results showed that there was little or no expression of MMP-13 or ADAMTS-5 in the knee joints of DP1 2/2 and WT mice at 3 months of age. At 9 months of age, the expression levels of ADAMTS-5 and MMP-13 remained almost undetectable in WT mice, but both were significantly elevated in the knee joints of DP1 2/2 mice. In the DMM model, the expression levels of MMP-13 and ADAMTS-5 were more elevated in articular cartilage from DP1 2/2 mice than that from WT control mice. Ex vivo studies with cartilage explants revealed that the rate of proteoglycan degradation following stimulation with IL-1a was higher in cartilage from DP1 2/2 mice compared to WT mice, suggesting that DP1 deletion enhanced the expression of cartilagedegrading enzymes. This is consistent with our previous findings showing that DP1 activation prevented the expression of MMP-13 and MMP-1 in cultured chondrocytes (34) . Taken together, these data strongly suggest that DP1 deletion mediates the up-regulation of MMPs and possibly other catabolic enzymes that exacerbate cartilage degradation.
In addition to cartilage destruction, OA both in humans and in experimental models is characterized by subchondral bone changes (3, 42) . Micro-CT analysis revealed extensive subchondral bone sclerosis, increased Figure 5 . Deletion of DP1 enhances interleukin-1a (IL-1a)-induced proteoglycan degradation in conditioned medium from cultured knee cartilage explants. Femoral heads from WT and DP1 2/2 mice were stimulated with 10 ng/ml IL-1a for 72 hours (or left untreated as a control [CTL]). Proteoglycan degradation in the conditioned medium from cultured explants was evaluated using a dimethylmethylene blue assay. Results are the mean 6 SD levels of sulfated glycosaminoglycan released per mg cartilage from 3 separate samples (n 5 3 samples per group; 2 mice per sample). * 5 P , 0.05. See Figure 1 for other definitions. mouse joints at age 15 months compared to WT mouse joints at the same age. We also noted that significant ectopic bone developed in the knee joints of DP1 2/2 mice at age 15 months. These parameters were also increased at 8 weeks following DMM surgery in both genotypes. Interestingly, in the DMM model, the magnitude of osseous changes was also more pronounced in DP1 2/2 mice. Thus, DP1 deficiency not only accelerates cartilage degradation, but also exacerbates subchondral bone changes.
Having demonstrated that DP1 deletion aggravates OA-like changes, we tested whether administration of the DP1 selective agonist BW245C could alter OA development in WT mice. We found that administration of a selective DP1 agonist reduced DMM-induced OA-like changes in both cartilage and bone. Interestingly, BW245C lost its beneficial effect in DP1 2/2 mice (data not shown), which excludes the possibility that cross-reactivity with distinct pathways may be responsible for the observed effect of BW245C.
Subchondral bone and cartilage behave as a functional unit both biochemically and mechanically (43) , and alteration in cell function metabolism in one tissue may affect both tissues during the process of OA.
Although our data clearly demonstrate a central role for DP1 in the pathogenesis of OA, it is unclear whether the exacerbation of OA in the absence of DP1 originates from alterations in bone or cartilage metabolism. Further analyses using cartilage-and bone-specific DP1-deficient mice would determine the tissue-specific role of DP1 during the progression of OA.
In addition to increased expression of MMP-13 and ADAMTS-5, DP1 deletion can exacerbate OA via magnification of inflammation. Indeed, several studies showed that DP1 deficiency amplifies, whereas DP1 activation dampens, inflammation in a number of models. For example, DP1 deficiency was shown to exacerbate skin inflammation in a model of contact hypersensitivity, and this was accompanied by increased production of interferon-g and IL-17 (25) . Moreover, chimeric mice with selective hematopoietic DP1 Figure 6 . Treatment with the DP1 agonist BW245C (BW) reduces the severity of OA in the destabilization of the medial meniscus (DMM) model. Ten-week-old WT mice were subjected to sham surgery (n 5 7 mice per group) or DMM surgery (n 5 8 mice per group). BW245C was administered intraperitoneally every day (0.5 mg/kg/day) beginning 1 day after surgery for 8 weeks. Phosphate buffered saline was used as a vehicle (Veh) control. The knee joints were collected and cartilage degradation was analyzed using Safranin O-fast green staining. A, Representative immunostained images are shown. The representative section was selected based on the average histologic severity score in each experimental group. B, Summed histologic OA severity scores were determined using the OA Research Society International scoring system. Symbols represent individual mice; horizontal lines indicate the mean. * 5 P , 0.05. C, Representative 3-dimensional reconstructions of the knee joint (obtained from micro-computed tomography images) are shown for sham-operated and DMM-operated mice (n 5 7-8 mice per group) at 8 weeks after surgery and following treatment with vehicle control or BW245C. See Figure 1 for other definitions. deficiency had enhanced airway inflammation, and administration of a selective DP1 agonist substantially suppressed the elicitation of inflammatory allergic reactions in an IL-10-dependent manner (21) . DP1 deficiency was also shown to aggravate lung inflammation in mice with bleomycin-induced acute lung injury, and this was associated with increased production of leukemia inhibitory factor, osteopontin, and chemokine (C-X-C motif) ligand 1 (16) .
In another study, treatment of DP1-deficient mice with a DP1 agonist was shown to be protective by decreasing inflammatory responses and fibrosis (17) . In addition, DP1 activation prevented skin lesions in a murine model of atopic dermatitis, likely acting through reduced recruitment of inflammatory cells into the dermis and increased production of the immunoregulatory cytokine IL-10 (22). Finally, BW245C was shown to prevent the progression of collagen-induced arthritis in mice by suppressing the secretion of the proinflammatory mediators IL-1, IL-6, and IL-17 and PGE 2 (44) . It is therefore possible that enhanced production of proinflammatory mediators could also contribute to the exacerbation of OA seen in DP1 2/2 mice. An additional mechanism by which DP1 deletion can exacerbate OA is by enhancing angiogenesis, a hallmark of OA (45) . Indeed, DP1 deficiency was shown to potentiate, and BW245C to inhibit, angiogenesis and vascular hyperpermeability (46) . Thus, the aggravated OA seen in DP1 2/2 mice can be attributed, at least partially, to enhanced angiogenesis.
The precise mechanisms by which deletion of DP1 exacerbates OA are likely multiple, but could involve down-regulation and impairment of the cAMP/ protein kinase A (PKA) pathway. Indeed, DP1 signals through the cAMP/PKA pathway (47) and we have previously shown that DP1 activation inhibits the expression of MMP-1 and MMP-13 in human chondrocytes via the cAMP/PKA pathway (34) . Moreover, several studies found that activation of the cAMP/PKA pathway in chondrocytes prevented the expression of various inflammatory and catabolic mediators such as nitric oxide, vascular endothelial growth factor, and MMPs (48-52). Therefore, it is possible that down-regulation of the cAMP/PKA pathway mediates, at least partially, the exacerbating effect of DP1 deletion on the progression of OA. DP1 deletion could be compensated for by DP2, the other PGD 2 receptor. This is unlikely, since both receptors usually transmit signals that are antagonistic (25) (26) (27) . On the other hand, we previously reported that DP2 agonists had no effect on the production of MMP-1 and MMP-13 in cultured chondrocytes (34) . Moreover, and in contrast to the findings in WT mice, treatment of DP1 2/2 mice with BW245C had no effect on the progression of DMM-induced OA (data not shown).
In conclusion, this study provides valuable insight into the role of DP1 in the pathophysiology of OA and suggests that targeting DP1 could be a potential therapeutic strategy for the prevention and treatment of OA.
